Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Diagnosis of primary open-angle glaucoma or ocular hypertension in each eye

• Requires bilateral treatment with an IOP-lowering medication

• Best corrected visual acuity of 20/100 or better in each eye

Exclusion Criteria:

• Use of oral, intramuscular, intravenous or topical ophthalmic corticosteroids within 2 months

• Inability to fast for up to 10 hours

• Prior refractive laser surgery (eg, LASIK, radial keratectomy, photorefractive keratectomy)

• Intraocular surgery or IOP-lowering laser surgery (eg, laser trabeculoplasty) within 6 months

• Current or anticipated use of artificial tears or any ocular medications aside from study medications during study

• Anticipated wearing of contact lenses during study